贛鋒鋰業(01772.HK):四名股東擬減持不超420萬股A股
格隆匯4月21日丨贛鋒鋰業(01772.HK)公佈,公司近日接獲公司股東瀋海博、楊滿英、熊劍浪、李華彪來函通知,瀋海博、楊滿英、熊劍浪、李華彪計劃自公告日期起15個交易日後的六個月內,通過集中競價交易、大宗交易或其他合法方式減持公司A股股份,瀋海博、楊滿英、熊劍浪、李華彪計劃減持的股份為其於公司A股首次公開發行前已認購的公司A股股份。
根據減持計劃,瀋海博、楊滿英、熊劍浪、李華彪計劃自公告日期起15個交易日後的六個月內合計減持公司A股不超過420萬股(即不超過公司截至公告日期的總股本的0.3249%)。減持計劃將通過集中競價交易、大宗交易或其他合法方式。減持價格視減持時市場價格確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.